Figure 2 from Loss of STK11 Suppresses Lipid Metabolism and Attenuates KRAS-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Year: 2024
Type: other
Abstract: KRAS-mutated NSCLC tumors display increased PDL1 expression. A and B, Tissue biopsies from 189 treatment-naïve patients with NSCLC were stained with either H&E or via IHC for PDL1. Representative images are shown for low and high expression in LUAD (N = 132) and SCC (N = 57) histologies. C, PDL1 TPS arranged by tumor histology. D, PDL1 TPS plotted against percentile CD274 mRNA expression. E, PDL1 TPS expression for tumor specimens obtained from the primary lung tumor (lung, N = 114), lymph node (LN, N = 31), or distant metastatic site (Met, N = 4). F and G, PDL1 TPS or CD274 mRNA expression for either KRAS-WT (N = 144) or KRAS mutated patients (MT, N = 45). H and I, PDL1 TPS or CD274 mRNA for either KRAS-WT or KRAS-MT patients arranged by tumor histology. J, PDL1 TPS or CD274 mRNA for either KRAS-WT or KRAS-MT patients arranged by tumor site. H&E, hematoxylin and eosin; NS, nonsignificant.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4402067660